Regression of macular edema secondary to branch retinal vein occlusion during anti-TNF-α therapy for rheumatoid arthritis

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 667-670

  Kachi, Shu ^a   Kobayashi, Kenshin ^a   Ushida, Hiroaki ^a   Ito, Yasuki ^a   Kondo, Mineo ^a   Terasaki, Hiroko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Branch retinal vein occlusion; Etanercept; Foveal thickness; Infliximab; Macular edema; Rheumatoid arthritis; Tissue necrosis factor alpha

Indexed keywords

BEVACIZUMAB; DICLOFENAC; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CASE REPORT; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PNEUMONIA; RECURRENCE RISK; RETINA FOVEA; RETINA MACULA EDEMA; RHEUMATOID ARTHRITIS; THICKNESS; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 77956117524     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: None     Document Type: Article

References (14)

1. Rehak J, Rehak M. Branch retinal vein occlusion: Pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33:111-131.
2. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984;98:271-282.
3. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005;140:695-702.
4. Osterloh MD, Charles S. Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol. 1988;106:1469-1471.
5. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419-425.
6. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
7. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother. 1997;31:1335-1338.
8. Luna JD, Chan CC, Derevjanik NL, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res. 1997;49: 268-280.
9. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648-650.
10. Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in Type 2 diabetes following treatment with the antitumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 2005;28:445-447.
11. Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology. 2009; Nov; 116:2158-2164.
12. Gandorfer A, Rohleder M, Grosselfinger S, Haritoglou C, Ulbig M, Kampik A. Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction. Am J Ophthalmol. 2005;139: 638-652.
13. Perez-Ruiz M, Ros J, Morales-Ruiz M, et al. Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. Hepatology. 1999;29:1057-1063.
14. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 2004;50:1636-1641.